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S376 Poster Session IIother management strategies. Associated increases in MAP, weight,
and serum creatinine at the time of PRES compared to baselinemea-
surements exemplify the importance of possible prevention through
more aggressive blood pressure and fluid management strategies in
this patient population.
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A COMPARISON OF CALCULATED GLOMERULAR FILTRATION RATE (GFR)
VS. MEASURED GFR IN A BLOOD AND MARROW TRANSPLANT POPULA-
TION
Shapiro, J.F.1, Ho, V.1, Wetzstein, G.1, Woodard, A.1, Rawal, B.2,
Pidala, J.3 1H. Lee Moffitt Cancer Center, Tampa, FL; 2H. Lee Moffitt
Cancer Center, Tampa, FL; 3H. Lee Moffitt Cancer Center, Tampa, FL
One of the most controversial topics in clinical practice is the es-
timation of a patient’s creatinine clearance (CrCl) and determination
of renal function. The gold standard in determining the glomerular
filtration rate (GFR) involves a 24 hour urine collection, which can
be onerous to patients and potentially inaccurate. As a result, the
most common method to determine GFR utilizes the Cockcroft-
Gault equation (CG) and Modification of Diet in Renal Disease
(MDRD) equation. One limitation with the CG equation is the de-
bate regarding which weight should be utilized.
Up until January 2010, a 24 hr collected CrCl was standard prac-
tice at Moffitt Cancer Center (MCC) for patients undergoing hema-
topoietic cell transplant (HCT) to assess patients’ renal function.
Because of the potential concerns with the collected 24 hour CrCl,
the department decided to calculate GFR utilizing the CG equation.
We performed a retrospective analysis to assess whether calculated
CrCl using actual, adjusted, or ideal bodyweight best correlated with
CrCldeterminedby 24hoururine collection.TheHCTdatabasewas
queried for all patients transplanted atMCCbetween January 1, 2009
throughDecember 31, 2009. From a total 355 patients, we randomly
selected 200 autologous and allogeneic patients for evaluation.
The correlation between the calculated CrCl based on actual, ad-
justed, and ideal body weight and collected CrCl was determined.
Pearson correlation coefficients of log-transformed data are pre-
sented in Table 1.The magnitude of correlation was greatest for
CrCl based on ideal body weight and collected CrCl, and statistical
comparison between competing approaches for calculated CrCl (ac-Table 1. Pearson Correlation Coefficients, N 5 200
L_CrCl_Actual L_CrCl_Ideal L_CrCl_Adj L_Collected_CRCl
L_CrCl_Actual* 1.00000 0.81541 p < 0.0001 0.96953 p < 0.0001 0.60256 p < 0.0001
L_CrCl_Ideal^ 0.81541 p < 0.0001 1.00000 0.92888 p < 0.0001 0.71345 p < 0.0001
L_CrCl_Adj& 0.96953 p < 0.0001 0.92888 p < 0.0001 1.00000 0.67072 p < 0.0001
L_Collected_CRCl 0.60256 p < 0.0001 0.71345 p < 0.0001 0.67072 p < 0.0001 1.00000
L5 log-transformed data; *5 Creatinine clearance based off of actual body weight; ^5 Creatinine clearance based off of ideal body weight; &5 Cre-
atinine clearance based off of adjusted body weight.cording to actual, adjusted, or ideal body weight) confirmed that the
correlation between ideal bodyweight and collectedwas significantly
greater than that for either actual (p \ 0.0001) or adjusted (p \
0.0001).
These data indicate that ideal body weight-based calculated creat-
inine clearance most closely approximates collected creatinine clear-
ance. Based on these results, we recommend ideal body weight for
such calculations for dosing of conditioning chemotherapy and im-
mune suppressive agents following HCT.
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PHARMACY DRIVEN POSACONAZOLE THERAPEUTIC MONITORING IN
A LEUKEMIA AND BONE MARROW TRANSPLANT CENTER
Leech, M.1, LaPorte, J.1, Mihelic, R.1, Sanacore, M.1, Sizemore, C.1,
Zhang, X.2, Penland, P.1, Holland, H.K.2, Morris, L.E.2,
Solomon, S.R.2, Bashey, A.2 1Blood and Marrow Transplant Program,
Northside Hospital, Atlanta, GA; 2Blood and Marrow Transplant Group
of Georgia, Atlanta, GA
Objectives: Posaconazole (POS) is an extended-spectrum triazole
with proven efficacy for antifungal prophylaxis in patients (pts) un-dergoing HSCT or treatment of acute leukemia. The FDA recom-
mends a goal POS average serum drug concentration of .700 ng/
ml. We implemented a pharmacy-driven POS therapeutic monitor-
ing program. Our primary objective was to see if pharmacy interven-
tion can be helpful in optimizing attainment of therapeutic POS
levels.
Methods: Forty-eight steady-state plasma trough POS levels (33 in
HSCT pts, 15 in pts undergoing acute leukemia therapy) performed
after at least 7 days of administration were analyzed.
Results: POS levels were .700 ng/ml in 19/48 (40%) pts. Mean
POS level was 790 ng/ml (range 53- 2960), and median was 602
ng/ml. Of the 29 levels\700ng/ml, there were 26 dose modifica-
tions. POS was changed to another antifungal in 13 pts, POS was
discontinued in 2 pts, and dose was increased in 11 pts. Of the 11
increased doses, 8 follow up levels were drawn with 4 pts achiev-
ing a documented therapeutic level. POS was being used as pro-
phylaxis (starting dose 200mg TID) in 31 pts (65%) and
empirically (starting dose 400mg BID) in 17 pts (35%). The high-
est dose used was 400mg QID in one pt with documented fungal
infection.
GVHD was present in 16 of 33 HSCT pts (48%), and ten of the
pts had gut GVHD at the time of level. POS levels were .700ng/
mL in 6/16 (38%) and 2/10 (20%) of all GVHD and gut GVHD
pts, respectively, although this was not statistically signficant. Pro-
ton-pump inhibitor or H2 antagonist therapy (PPI/H2) was admin-
istered concurrently with 42/48 (88%) of levels, although the use of
these drugs had no apparent effect on therapeutic levels. Leukemia
pts were significantly less likely to achieve therapeutic POS levels
when compared to HSCT pts (27% vs 61%, p 5 0.029). Other
than treatment group, we found no other factors that correlated
with achieving therapeutic levels.
Conclusion: The pharmacy based implementation of POS thera-
peutic monitoring revealed that achievement of recommended
POS levels remains a challenge in an unselectedHSCT and leukemic
population. This program enabled documentation of compliance
and allowed an attempt at improvement of POS levels by dose adjust-
ment. Pharmacists counseled pts on ways to increase absorption by
taking with a high fat meal, nutritional supplement, or acidic carbon-
ated beverage, and by stopping their PPI/H2.470
REDUCED-DOSE MELPHALAN VS. STANDARD DOSE MELPHALAN FOR
AUTOLOGOUS STEM CELL TRANSPLANTATION: IS THERE A DIFFERENCE
IN OUTCOME?
Maewal, I.1, Gulbis, A.1, Champlin, R.E.2, Qazilbash, M.H.2 1MD
Anderson Cancer Center, Houston, TX; 2MD Anderson Cancer Center,
Houston, TX
Background: Based on the results of randomized phase III trials,
melphalan 200 mg/m2 IV (MEL 200) is considered the standard
preparative regimen for autologous hematopoietic stem cell trans-
plantation (auto-HCT) for multiple myeloma. However, reduced
doses of melphalan, 140 mg/m2 (MEL 140) or 180 mg/m2
(MEL 180), are often used in older patients or patients with renal
dysfunction.
Methods:The primary objective was to determine if there was a dif-
ference in toxicity, treatment-related mortality, response rate, pro-
gression-free survival or overall survival in patients that received
lower doses of melphalan for auto-HCT. From June 1, 1996 through
December 25, 2010, 1425 patients received auto-HCT at our insti-
tution. We identified 57 patients that received MEL 140 or 180 and
